Business
Avivagen Announces Results From Its Annual General Meeting April 8, 2020
Avivagen Announces Results From Its Annual General Meeting April 8, 2020.
About this update from Avivagen, Inc.
[{"type":"text","content":"Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”), announces that at the Corporation’s Annual General Meeting (AGM) held today the Corporation’s shareholders voted to support all of the resolutions that came before the meeting. The resolutions included the reappointment of McGovern Hurley LLP as Avivagen’s auditor and the election of directors.The voting results in respect of the election of directors are detailed below:Nominee% Of Votes Cast At The MeetingWhich Were Cast for the Election of Directors% Of Votes Cast At The MeetingWhich Were Withheld From VotingKym Anthony97.8%2.2%Graham Burton99.3%0.7%Aubrey Dan98.5%1.5%David Hankinson78.3%21.7%Jeffrey Kraws98.5%1.5%Paul Mesburis98.8%1.2%About AvivagenAvivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications. By unlocking an overlooked facet of β-carotene activity, a path has been opened to safely and economically support immune function, thereby promoting general health and performance in animals. Avivagen is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release. About OxC-beta™ Technology and OxC-beta™ LivestockAvivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Taiwan, New Zealand, Thailand, Mexico, Australia and Malaysia.Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product perf...